Abstract Review Categories

100s - Red Cell Physiology and Disorders

Categories 101–114 exclude studies of transplantation or gene therapies for red cell disorders and anemias, which should be submitted to 700s or 801.

101. Red Cells and Erythropoiesis, Excluding Iron

Basic, translational, clinical, and epidemiological studies of erythropoiesis and normal or abnormal RBC structure and function. Includes anemias related to red cell underproduction, overproduction (other than myeloproliferative disorders, see 600s), autoimmune destruction, nutritional deficiencies (excluding iron which belong in 102), infections of erythroid cells (e.g. malaria), and systemic diseases, inflammation, and aging, other than disorders linked to perturbed iron metabolism (see 102) or clonal hematopoiesis (see 503). Anemias related to paroxysmal nocturnal hemoglobinuria, Diamond-Blackfan anemia or other acquired or inherited bone marrow failure syndromes, see 508 or 509. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

102. Iron Homeostasis and Biology in Physiological and Pathological Conditions

Basic, translational, clinical, and epidemiological studies of iron homeostasis and acquired or congenital disorders resulting in iron overload, iron deficiency, or heme pathway dysfunction (e.g. porphyrias). Also includes abnormalities of iron homeostasis in the context of inflammation or aging, and iron dysregulation studies specifically in the context of hemoglobinopathies (e.g. SCD). For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

112. Thalassemia and Globin Gene Regulation

Basic, translational, clinical, and epidemiological studies of thalassemias, and investigation of mechanisms controlling hemoglobin production. Encompasses risk factors, diagnosis, complications, drug treatments, pharmacologic interactions, and disease course. Studies of iron dynamics in the context of thalassemia are appropriate. Studies of thalassemic hemoglobin disorders such as sickle thalassemia, see 113 or 114. For transplantation and gene therapies, see 700s or 801. For health services and quality improvement studies, see 900; and for outcomes research, including registry or Real-World studies, see 904.

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational

Basic and translational studies of sickle cell disease, sickle cell trait, sickle thalassemia, and other hemoglobinopathies.

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological

Clinical and epidemiological studies of sickle cell disease, sickle cell trait, sickle thalassemia and other hemoglobinopathies. Encompasses risk factors, diagnosis, complications, disease course and treatments. For transplantation and gene therapies, see 700s or 801. For health services and quality improvement studies, see 900; and for outcomes research, including registry or Real-World studies, see 904.

200s - Leukocytes, Inflammation, and Immunology

These categories generally exclude hematopoiesis (500s), leukemias (600s), or aspects of leukocyte biology related to transplantation, cell processing or gene therapies (700s and 801).

201. Granulocytes, Monocytes, and Macrophages

Basic, translational, clinical, and epidemiological studies of normal or abnormal neutrophils, monocytes, dendritic cells, histiocytes, eosinophils, basophils, or mast cells, including acquired or congenital disorders of the production, function, or trafficking of these cells, including hematologic hyperinflammatory syndromes (HLH, MAS, etc.) and WHIM, and excluding MDS, MPD and AML (see 600s). Treatment of neutropenia or other myeloid cellular deficiencies with cytokines or other drugs are appropriate, including applications in non-hematologic diseases, but those focused on treatment of cytopenias resulting from hematologic malignancies or their treatment would be better suited for 600s or 700s. Abstracts focused on neutropenia in the context of bone marrow failure or cancer predisposition syndromes, see 508 or 509. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders

Basic, translational, clinical, and epidemiological studies of the development and function of B cells, T cells, natural killer cells, or other lymphoid lineages, including acquired or congenital immunodeficiencies and immune dysregulation disorders. Studies in the context of infections, immunotherapies, or other environmental challenges are appropriate, as well as investigations of interleukins, interferons, or factors which modulate immune cell function. Studies of Castleman disease, including basic, translational, clinical and outcomes, are included in this category. Excludes pre-malignant and malignant lymphocyte and plasma cell disorders (see 600s). Clinical and manufacturing/engineering studies of lymphoid cells for adoptive transfer, see 704, 711, or categories encompassing the specific hematologic indications. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

300s - Hemostasis, Thrombosis, and Vascular Wall Biology

301. Platelets and Megakaryocytes: Basic and Translational

Basic and translational studies of all aspects of platelet production, biology and function, including von Willebrand factor-platelet interactions. May include diagnostic assays or laboratory tests for platelet function and platelet disorders. Studies of hematopoiesis focused on the impact of hematopoietic stem and progenitor cells on platelet production may be better suited for 500s.

311. Disorders of Platelet Number or Function: Clinical and Epidemiological

Clinical and epidemiological studies of thrombocytopenias, including autoimmune, alloimmune, infectious and drug-related disorders; as well as intrinsic and secondary abnormalities of platelet function. Encompasses risk factors, diagnosis, complications, treatments, and disease course. Clinical studies of thrombotic microangiopathies/thrombocytopenias (TTP/HUS, HIT, VITT, anti-phospholipid syndromes, COVID-19 or vaccine related) belong in 331. Abnormalities in platelet counts or function related to myeloproliferative disorders or other hematologic malignancies belong in 600s. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

321. Coagulation and Fibrinolysis: Basic and Translational

Basic or translational studies of clotting factors, fibrinolytic proteins, and related molecules which take part in blood coagulation or fibrinolysis, as well as enzymes or proteases involved in their synthesis or degradation. Interactions of von Willebrand’s disease with platelets may be better suited for 301. Investigations of vascular disorders resulting primarily in bleeding also belong in this category. May include development of diagnostic assays or laboratory tests for bleeding disorders and coagulopathies.

322. Hemophilia A and B: Clinical and Epidemiological

Clinical and epidemiological studies of congenital hemophilia A and B (acquired hemophilias see 323). Encompasses risk factors, diagnosis, complications, treatments, pharmacologic interactions, and disease course. Studies of the processing of fractionated blood or plasma components used to treat hemophilias, see 401. Gene therapies for these disorders, see 801. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological

Clinical and epidemiological studies of congenital and acquired disorders of coagulation (excluding congenital hemophilia A and B), fibrinolysis, von Willebrand’s disease, or other bleeding diatheses, including vascular disorders resulting primarily in bleeding, such as heredity hemorrhagic telangiectasia. Encompasses risk factors, diagnosis, complications, treatments, pharmacologic interactions, and disease course. Excludes studies of abnormal bleeding due to thrombocytopenia or platelet dysfunction (see 311). Studies of the processing of fractionated blood or plasma components used to treat bleeding disorders, see 401. Gene therapies for these disorders see 801. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational

Basic and translational studies of vascular and endothelial cell biology, angiogenesis, hypercoagulability, thrombosis, and thrombotic microangiopathies/thrombocytopenias (e.g. congenital or acquired forms of TTP/HUS, heparin-induced thrombocytopenia, HELLP, VITT, COVID-19 thrombosis, antiphospholipid syndromes, and related disorders). May include development of diagnostic assays or laboratory tests for these disorders. Basic/translational studies of platelet number and function, see 301 and of coagulation and fibrinolysis, see 322.

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological

Clinical and epidemiological studies of risk factors, diagnosis, outcomes, complications, prognosis, and treatment of thrombotic microangiopathies/thrombocytopenias, including congenital or acquired forms of TTP/HUS, heparin-induced thrombocytopenia, antiphospholipid syndromes, HELLP, vaccine-induced thrombotic thrombocytopenia (VITT), and other related acquired and inherited disorders. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

332. Thrombosis and Anticoagulation: Clinical and Epidemiological

Clinical and epidemiological studies of risk factors, diagnosis, complications, prognosis, and treatment of thromboembolism and inherited and acquired hypercoagulability states, including thromboses associated with infections or cancer. May also include design and testing of assays for monitoring of anticoagulant and antithrombotic therapies. Studies focused on thrombotic microangiopathies/thrombocytopenias (e.g. TTP/HUS, HIT, antiphospholipid syndromes, HELLP, VITT), see 331. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

400s - Transfusion Medicine

401. Blood Transfusion

Basic, translational, clinical, and epidemiological studies of collection, handling, storage, modification, or administration of blood or blood components. Also includes RBC or platelet antigen and antibody testing, prevention/detection/treatment of blood-borne infections, and complications of transfusions. Cell processing for transplantation or adoptive cell therapies, see 704 and 711. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

500s - Hematopoiesis

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational

Basic and translational studies of the cellular and molecular biology of hematopoietic stem and progenitor cells (HSPCs), including during development. Studies focused on differentiation of HSPCs from pluripotent stem cells are also appropriate. Studies of cytokines and cytokine receptors or other molecules controlling hematopoiesis are appropriate. Excludes studies of HSPC mobilization and engraftment (see 701), clinical collection and processing of HSPCs (see 711), or the interaction of microenvironmental cells with HSPCs (see 506). Studies focused solely on erythropoiesis should be submitted to 101 and solely on megakaryopoiesis to 301.

503. Clonal Hematopoiesis, Aging, and Inflammation

Basic, translational, clinical, and epidemiological studies investigating mechanisms (including inflammation), risk factors, complications, treatment, prognosis, and outcomes related to acquired somatic clonal mutations and/or aging of hematopoietic stem and progenitor cells. Studies focused solely on anemias of inflammation or aging should be submitted to 101 or 102. VEXAS would also be appropriate for this category. Studies focused on the impact of the bone marrow microenvironment should be submitted to 506. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

506. Bone Marrow Microenvironment

Basic, translational, clinical, and epidemiological studies of the bone marrow hematopoietic microenvironment, including studies focused on cellular or matrix component(s) or factor(s) secreted from cellular components participating in the modulation of hematopoiesis and influencing either normal, pre-leukemic, or leukemic stem cells. Includes studies of mesenchymal stromal cells or other microenvironmental cells in vitro and in animal models, as well as early phase clinical trials involving transplantation of these cells for hematopoietic support or immune modulation.

508. Bone Marrow Failure: Acquired

Basic, translational, clinical, and epidemiological studies of acquired bone marrow failure, including aplastic anemia, hypo-productive cytopenias, paroxysmal nocturnal hemoglobinuria, and VEXAS. For inherited bone marrow failure and/or cancer predisposition syndromes, see 509. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital

Basic, translational, clinical, and epidemiological studies of congenital/inherited bone marrow failure and blood cancer predisposition syndromes, e.g. Fanconi anemia, Diamond-Blackfan anemia, telomeropathies, Shwachman-Diamond syndrome, GATA2 deficiency, RUNX1 deficiency, DDX4-related syndromes, and any other germline bone marrow failure or blood cancer predisposition syndromes. For health services and quality improvement studies, see 901; and for outcomes research, including registry or Real-World studies, see 905.

600s - Hematologic Malignancies

These categories exclude studies of normal hematopoietic cells (see 500s), unless directly linked to oncogenesis. Studies of allogeneic transplantation in hematologic malignancies, including comparisons to drug therapies, see 700s. Health services and outcomes research focusing on hematologic malignancies see 900s.

602. Myeloid Oncogenesis: Basic

Basic and mechanistic studies of gene expression, epigenetics, DNA repair, metabolism and/or other cellular functions disrupted in myeloid or non-lineage specific oncogenesis. Translational studies focused on specific malignancies and/or samples from patients with these malignancies may be more appropriate for other 600s categories (see below).

603. Lymphoid Oncogenesis: Basic

Basic and mechanistic studies of gene expression, epigenetics, DNA repair, metabolism and/or other cellular functions disrupted in lymphoid oncogenesis. Translational studies focused on specific malignancies and/or on samples from patients with these malignancies may be more appropriate for other 600 categories (see below).

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms

Basic, translational, preclinical animal model, and very early phase clinical studies of the development and interactions of non-cellular therapeutic agents and their receptors, binding sites or ligands as related to myeloid neoplasms. Includes studies of pharmacokinetics, drug transport, metabolism, drug activity, and drug resistance. Discovery and screening studies of small molecule inhibitors and approaches involving chemical biology may be more appropriate for 802.

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms

Basic, translational, preclinical animal model, and very early phase clinical studies of the development and interactions of non-cellular therapeutic agents and their receptors, binding sites or ligands as related to lymphoid neoplasms. Includes studies of pharmacokinetics, drug transport, metabolism, drug activity, and drug resistance. Discovery and screening studies of small molecule inhibitors and approaches involving chemical biology may be more appropriate for 802.

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological

Clinical and epidemiological studies of acute lymphocytic leukemias, including risks factors, diagnosis, complications, treatment of complications, prognosis, and long-term outcomes such as quality of life. Clinical trials of treatment modalities belong in 613. Translational biomarker, “omics” or measurable residual disease studies may be more appropriate for 618. For health services and quality improvement studies, see 902; and for outcomes research, including registry or Real-World studies, see 906.

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation

Clinical studies of drug therapies, biological agents, and cellular or non-cellular immunotherapies. Includes studies of disease response, survival, quality of life, and other parameters related to treatment. For cellular therapy abstracts focused primarily on early phase trials of novel cellular therapies, cellular therapy toxicities, or product manufacturing see 704 or 711. For allogeneic transplantation, see 700s. For health services and quality improvement studies, see 902; and for outcomes research, including registry or Real-World studies, see 906.

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis

Translational, epidemiological, and clinical correlation studies of biologic markers and characteristics, such as biochemical, histochemical, metabolic, genetic, karyotypic, or morphologic parameters in the diagnosis and prognosis of acute lymphoblastic leukemia. May also include measurable residual detection and preclinical or developmental studies of markers intended for eventual application to diagnosis and prognosis. This is the appropriate category for translational research in the molecular “omics” of human ALL.

615. Acute Myeloid Leukemias: Clinical and Epidemiological

Clinical and epidemiological studies of acute myeloid leukemias, including risk factors, diagnosis, complications, treatment of complications, prognosis, and long-term outcomes such as quality-of-life. Clinical trials of measurable residual disease studies may be more appropriate for 618 or 619. For health services and quality improvement studies, see 903; and for outcomes research, including registry or Real-World studies, see 908.

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies

Clinical studies of investigational (non-commercially available) drug therapies, biological agents, and/or cellular or non-cellular immunotherapies. Includes studies of disease response, complications, survival, quality of life, and other parameters related to treatment. For cellular therapy abstracts focused primarily on early phase trials of novel cellular therapies, cellular therapy toxicities, or product manufacturing, see 704 or 711. For health services and quality improvement studies, see 903; and for outcomes research, including registry or Real-World studies, see 908.

617. Acute Myeloid Leukemias: Commercially Available Therapies

Clinical studies of commercially available drug therapies, biological agents, or immunotherapies. Includes studies of disease response, complications, survival, quality of life, and other parameters related to treatment. For allogeneic transplantation, see 700s. For health services and quality improvement studies, see 903; and for outcomes research, including registry or Real-World studies, see 908.

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis

Translational, epidemiological, and clinical correlation studies of biologic markers and characteristics, such as biochemical, histochemical, metabolic, genetic, karyotypic, or morphologic parameters in the diagnosis and prognosis of AML. May also include preclinical or developmental studies of biomarkers intended for eventual application to diagnosis and prognosis. This is the appropriate category for translational research in the molecular “omics” of human AML For studies focused on disease burden/measurable residual disease in relation to prognosis or treatment decisions, or on development of measurable residual disease assays, see 619.

619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment

Translational, developmental, and clinical correlation studies of disease burden/measurable residual disease in the prognosis and treatment of AML. May also include development and validation of measurable residual disease assays.

621. Lymphomas: Translational – Molecular and Genetic

Translational, epidemiological, and clinical correlation studies of genetic, karyotypic, gene expression, and/or epigenetic changes and risk factors in Hodgkin and non-Hodgkin lymphomas, including the development and utilization of preclinical animal models. This is the appropriate category for translational research in the molecular “omics” of lymphomas. May also include measurable residual detection and preclinical or developmental studies of markers intended for clinical and prognostic applications. Basic mechanistic investigations of neoplastic transformation may be better suited for 603, and pharmacologic development and testing of therapeutic agents for 605.

622. Lymphomas: Translational – Non-Genetic

Translational, epidemiological, and clinical correlation studies of Hodgkin and non-Hodgkin lymphomas focused on microenvironment, immune response, metabolic, proteomic, morphologic, cell of origin, or other non-genetic risk factors, including the development and utilization of preclinical animal models. Basic mechanistic investigations of neoplastic transformation may be better suited for 603, and pharmacologic development and testing of therapeutic agents for 605.

623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological

Clinical trials, retrospective/observational studies, and epidemiological studies of risk factors, diagnosis, complications, treatment of complications, prognosis, outcomes, quality of life, and treatments (excluding transplantation and cellular immunotherapies) in indolent B cell non-Hodgkin lymphomas; including mantle cell, follicular, Waldenstrom’s, and marginal zone lymphomas, mucosal associated lymphoid tissue (MALT), and hairy cell leukemia. For studies of the development and application of biomarkers or “omics,” see 621 or 622. For allogeneic transplantation, see 700s. For cellular therapy abstracts focused primarily on early phase trials of novel cellular therapies, cellular therapy toxicities, or product manufacturing, see 704 or 711; later stage cellular therapy trials for these lymphomas are appropriate for this category (623). For health services and quality improvement studies, see 902; and for outcomes research, including registry or Real-World studies, see 906.

624. Hodgkin Lymphomas: Clinical and Epidemiological

Clinical trials, retrospective/observational studies, and epidemiological studies of risk factors, diagnosis, complications, treatment of complications, prognosis, quality-of-life, outcomes, and treatments (excluding allogeneic transplantation) for Hodgkin lymphoma. For studies of the development and application of biomarkers or “omics,” see 621 or 622. For allogeneic transplantation, see 700s. For cellular therapy abstracts focused primarily on early phase trials of novel cellular therapies, cellular therapy toxicities, or product manufacturing, see 704 or 711; later stage cellular therapy trials for these lymphomas are appropriate for this category (624). For health services and quality improvement studies, see 902; and for outcomes research, including registry or Real-World studies, see 906.

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological

Clinical trials, retrospective/observational studies, and epidemiological studies of risk factors, diagnosis, complications, treatment of complications, prognosis, quality-of-life, outcomes, and treatments (excluding allogeneic transplantation) for T cell, natural killer (NK) cell and T/NL cell lymphomas; including mycosis fungoides and Sezary syndrome. For studies of the development and application of biomarkers or “omics,” see 621 or 622. For allogeneic transplantation, see 700s. For cellular therapy abstracts focused primarily on early phase trials of novel cellular therapies, cellular therapy toxicities, or product manufacturing, see 704 or 711; later stage cellular therapy trials for these lymphomas are appropriate for this category (625). For health services and quality improvement studies, see 902; and for outcomes research, including registry or Real-World studies, see 906.

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials

Clinical and epidemiological studies of risk factors, diagnosis, complications, treatment of complications, prognosis, and long-term outcomes including quality of life in aggressive non-Hodgkin lymphomas; including diffuse large B cell and subtypes, Burkitt, and primary CNS lymphomas, and post-transplant lymphoproliferative disorders. For studies of the development and application of biomarkers or “omics,” including using clinical trial samples, see 621 or 622. For treatment trials, see 627, 628 or 629; please note that treatment trials inappropriately submitted to this category will be reassigned to 627-629. For health services and quality improvement studies, see 902; and for outcomes research, including registry or Real-World studies, see 906.

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies

Clinical trials focused on targeted or pharmacologic treatments (excluding allogeneic transplantation and cellular therapies, which should be submitted to 628, and excluding non-cellular immunotherapy including bispecific antibodies, which should be submitted to 629), complications of treatments, outcomes, and quality-of-life related to targeted or pharmacologic treatments for aggressive non-Hodgkin lymphomas; including diffuse large B cell and subtypes, Burkitt, and primary CNS lymphomas, and post-transplant lymphoproliferative disorders. For studies of the development and application of biomarkers or “omics,” see 621 or 622. For clinical trials focusing primarily on non-cellular immunotherapy for aggressive lymphomas, including bispecific antibodies, see 629. For allogeneic transplantation, see 700s. For cellular therapy clinical trials see 628 (late stage and commercial), or 704 and 711 (earlier stage, toxicities, and manufacturing). For health services and quality improvement studies, see 902; and for outcomes research, including registry or Real-World studies, see 906.

628. Aggressive Lymphomas: Cellular Therapies

Clinical trials, registry and Real-World data focused on cellular therapies, including disease outcomes and quality-of-life related to treatments for aggressive non-Hodgkin lymphomas; including diffuse large B cell and subtypes, Burkitt, and primary CNS lymphomas; and post-transplant lymphoproliferative disorders. Studies including patients with multiple histologies should be submitted to this category if aggressive B cell histology predominates. For studies of the development and application of biomarkers or “omics,” see 621 or 622. For allogeneic transplantation, see 700s. For cellular therapy abstracts focused primarily on early phase trials of novel cellular therapies, cellular therapy toxicities, or product manufacturing, see 704 or 711. For clinical trials focusing primarily on targeted or pharmacologic therapies for aggressive lymphomas, see 627. For clinical trials focusing primarily on immunotherapy for aggressive lymphomas, including bispecific antibodies, see 629. For health services and quality improvement studies, see 902; and for outcomes research, see 906.

629: Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies

Clinical trials focused on immunotherapy including antibody drug conjugates, immune checkpoint inhibitors and bispecific antibodies, even if combined with chemotherapy, as well as studies focused on complications of such treatments, outcomes, and quality-of-life when given for aggressive non-Hodgkin lymphomas; including diffuse large B cell and subtypes, Burkitt, and primary CNS lymphomas, and post-transplant lymphoproliferative disorders. Studies of vaccination are also appropriate for this category. For studies of the development and application of biomarkers or “omics,” see 621 or 622. Clinical trials of targeted and pharmacologic therapies should be submitted to 627, and studies of transplantation and cellular therapies should be submitted to 628. For allogeneic transplantation more generally, see 700s. For cellular therapy clinical trials see 628 (late stage and commercial), or 704 and 711 (earlier stage, toxicities, and manufacturing). For health services and quality improvement studies, see 902; and for outcomes research, including registry or Real-World studies, see 906.

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational

Basic and translational studies of chronic myeloid leukemia and myeloproliferative syndromes, including myelofibrosis, essential thrombocythemia, polycythemia vera, clonal mast cell disorders, clonal eosinophilias, and malignant histocytoses. For studies focused on application of molecular diagnostic tools for diagnosis or prognosis, see 632 or 634. Basic mechanistic investigations of neoplastic transformation at a genetic/epigenetic/gene expression/metabolic or signal transduction level may be better suited for 602, and pharmacologic development and testing of therapeutic agents for 604.

632. Chronic Myeloid Leukemia: Clinical and Epidemiological

Clinical and epidemiological studies of chronic myeloid leukemia, including risk factors, diagnosis, complications, prognosis, treatments, and long-term outcomes including quality-of-life. For allogeneic transplantation, see 700s. For health services and quality improvement studies, see 903; and for outcomes research, including registry or Real-World studies, see 908.

634. Myeloproliferative Syndromes: Clinical and Epidemiological

Clinical and epidemiological studies of myeloproliferative syndromes, including myelofibrosis, essential thrombocythemia, polycythemia vera, myeloproliferative mast cell and eosinophilic, and malignant histiocytosis. Includes genetic and other risk factors, diagnosis, complications, prognosis, treatment, and long-term outcomes including quality-of-life. For allogeneic transplantation, see 700s. For health services and quality improvement studies, see 903; and for outcomes research, including registry or Real-World studies, see 908.

636. Myelodysplastic Syndromes: Basic and Translational

Basic and translational studies of myelodysplastic syndromes, including CMML. For studies focused on the application of molecular diagnostic tools in diagnosis or prognosis, see 637. Basic mechanistic investigations of neoplastic transformation at a genetic/epigenetic/gene expression/metabolic or signal transduction level may be better suited for 602, and studies focused on pharmacologic development of therapeutic agents for 604.

637. Myelodysplastic Syndromes: Clinical and Epidemiological

Clinical and epidemiological studies of myelodysplastic syndromes, including RAEB and CMML, encompassing risk factors, diagnosis, complications, prognosis, outcomes, treatments, and long-term outcomes including quality-of-life. For allogeneic transplantation, see 700s. For health services and quality improvement studies, see 903; and for outcomes research, including registry or Real-World studies, see 908.

641. Chronic Lymphocytic Leukemia: Basic and Translational

Basic and translational studies of chronic lymphocytic leukemia, including all aspects of disease biology, preclinical model development, and development of diagnostic or prognostic biomarkers including “omics”. Basic mechanistic investigations of neoplastic transformation at a genetic/epigenetic/gene expression/metabolic or signal transduction level may be better suited for 603, and pharmacologic development of new therapeutic agents for 605. For studies on the use of molecular diagnostic tools for diagnosis or prognosis see 642.

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological

Clinical and epidemiological studies focused on CLL, including risk factors, diagnosis, complications, prognosis, pharmacologic and cellular therapies (excluding allogeneic transplantation), and long-term outcomes including quality-of-life. Includes the use of biomarkers or genomics for diagnosis or prognosis. For allogeneic transplantation, see 700s. For cellular therapy abstracts focused primarily on early phase trials of novel cellular therapies, cellular therapy toxicities, or product manufacturing, see 704 or 711; later stage cellular therapy trials for CLL are appropriate for this category (642). For health services and quality improvement studies, see 902; and for outcomes research, including registry or Real-World studies, see 906.

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational

Basic and translational studies of multiple myeloma, MGUS, amyloidosis and other plasma cell dyscrasias. Includes interactions of myeloma cells with the microenvironment, such as bone, and with the immune system, and use of pre-clinical models to investigate pathophysiology and therapies. Basic mechanistic investigations of neoplastic transformation at a genetic/epigenetic/gene expression/metabolic or signal transduction level may be better suited for 603, and pharmacologic development of new therapeutic agents for 605.

652: MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological

Clinical and epidemiological studies of risk factors, diagnosis, complications, treatment, prognosis, quality-of-life, and analysis of diagnostic or prognostic biomarkers including “omics” in MGUS, amyloidosis, and other plasma cell dyscrasias (not including multiple myeloma). For health services and quality improvement studies, see 902; and for outcomes research, including registry or Real-World studies, see 907.

653. Multiple Myeloma: Clinical and Epidemiological

Clinical or epidemiological studies of risk factors, diagnosis, complications, treatment of complications, prognosis, or quality-of-life in multiple myeloma. For analysis of diagnostic, or prognostic or translational biomarkers including “omics” or MRD in multiple myeloma, see 656. For prospective clinical trials, please see 654 or 655. For studies about CAR-T therapy for multiple myeloma including Real-World treatment, outcome, toxicity and risk factors, see 655. For clinical and epidemiological studies in MGUS, amyloidosis, or other non-myeloma plasma cell dyscrasias, see 652. For clinical treatment trials, see 654-655. For health services and quality improvement studies, see 902; and for outcomes research, see 907.

654. Multiple Myeloma: Pharmacologic Therapies

Clinical trials of drugs, biological agents, and non-cellular immunotherapies for multiple myeloma. Includes regimens incorporating autologous HSPC transplantation. For treatment of MGUS, amyloidosis, or other non-myeloma plasma cell dyscrasias see 652. For allogeneic transplantation, see 700s. For cellular therapy clinical trials, see 655 (late stage and commercial), or 704 and 711 (earlier stage, toxicities, and manufacturing). For health services and quality improvement studies, see 902; and for outcomes research, see 907.

655. Multiple Myeloma: Cellular Therapies

Clinical trials and Real-World outcomes of cellular immunotherapies for multiple myeloma. For allogeneic transplantation, see 700s. For cellular therapy abstracts focused primarily on early phase trials of novel cellular therapies, cellular therapy toxicities, or product manufacturing, see 704 or 711. For health services and quality improvement studies, see 902; and for outcomes research, see 907.

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease

Translational, epidemiological, and clinical correlation studies of biologic markers and characteristics, such as biochemical, histochemical, metabolic, genetic, karyotypic, or morphologic parameters in the diagnosis and prognosis of multiple myeloma. May include preclinical or developmental studies of biomarkers intended for eventual application to diagnosis and prognosis. This is the appropriate category for translational research in the molecular “omics” of human multiple myeloma or for studies focused on disease burden/minimal residual disease in relation to prognosis or treatment decisions.

700s - Transplantation and Adoptive Cell Therapies

701. Experimental Transplantation: Basic and Translational

Preclinical investigations of topics relevant to HSPC transplantation, including conditioning regimens, HSPC mobilization, engraftment, rejection, transplant complications, disease activity, immune function, GVHD, and graft-versus-tumor effects.

702. CAR-T Cell Therapies: Basic and Translational

Basic, translational, and developmental studies of CAR-T cells. Studies focused on understanding and mitigating toxicities of CAR-T cells are also appropriate. Studies focused on development or improvement of the manufacturing of CAR-T cells, see 711. Studies focused on other adoptive cellular therapies, see 703.

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational

Basic, translational, and developmental studies of cellular immunotherapies incorporating T cells, NK cells, regulatory cells, dendritic cells, and other cell populations designed to treat malignancies or other hematologic diseases. This category excludes CAR-T cells (see 702) but includes all other engineered immune cells. Studies focused on understanding and mitigating toxicities of cellular immunotherapies cells are also appropriate. Studies focused on development or improvement of the manufacturing of cellular therapies, see 711.

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities

Phase 1 or other early phase clinical studies of novel (non-commercial) cellular immunotherapies or novel applications of cellular immunotherapies, including CAR-T cells and other adoptive engineered and non-engineered immunotherapies. Clinical studies focused on the diagnosis, treatment, and avoidance of toxicities such as cytokine release syndrome or other aspects of cellular immunotherapies with relevance across disease targets, even related to later stage clinical trials, would be appropriate. Phase 2 and 3 later phase clinical trials and those trials studying commercial immunotherapies belong in disease specific categories. Studies investigating cellular therapies to improve immune reconstitution or treat viral infections in the context of allogeneic transplantation, see 722. For studies focused on manufacturing of cellular products, see 711. For health services and quality improvement studies and for outcomes research on cellular immunotherapies, including registry or Real-World studies, see 900s.

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products

Development and manufacturing of hematopoietic stem and progenitor cell (HSPC) products, CAR-T cells, and other adoptive cell therapies. Encompasses clinical mobilization of HSPCs, collection of starting cells (including via leukapheresis, marrow harvest or cord blood procurement), purification of HSPCs or immune cells, cryopreservation, expansion, and scale-up and optimization of cellular engineering. Experimental studies or clinical development of mesenchymal or other stromal cell populations see 506. Basic and translational studies of HSPC mobilization, engraftment, or expansion, see 701.

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities

Clinical and epidemiological allogeneic transplantation studies encompassing engraftment, rejection and chimerism, conditioning regimens, acute toxicities other than GVHD, infectious complications and prophylaxis, and supportive care such as transfusions and cytokines. For health services and quality improvement studies and for outcomes research, including registry or Real-World studies, see 900s.

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution

Clinical and epidemiological studies covering risk factors, biomarkers, detection, prevention, and management related to acute and chronic graft-versus-host disease (GVHD) and to immune reconstitution and vaccine responses following allogeneic transplantation. May include post-transplantation cellular therapies designed to improve immune function or treat GVHD. For health services and quality improvement studies and for outcomes research, including registry or Real-World studies, see 900s.

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence

Clinical and epidemiological studies, including risk factors, detection, treatment and prevention, focusing on late effects of transplantation, including fertility, growth and development, secondary malignancies, and quality of life. Also includes studies of treatment of disease recurrence post-transplantation and second transplants. Immune reconstitution and post-transplantation vaccination responses, see 722. For health services and quality improvement studies and for outcomes research, including registry or Real-World studies, see 900s.

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies

Clinical and epidemiological studies focusing on disease activity and survival following allogeneic transplantation, including risk factors and biomarkers for outcomes. Includes trials comparing allogeneic transplantation to other non-transplantation therapies in specific diseases. Excludes studies on specific acute and late toxicities (see 721-723). For health services and quality improvement studies and for outcomes research, including registry or Real-World studies, see 900s.

800s - Gene Therapies, Chemical Biology, and Emerging Diagnostics

801. Gene Therapies

Basic, translational, and clinical studies of gene therapies, including gene addition, gene editing, and other approaches targeting genes, as applied to benign and malignant blood diseases. Studies focused specifically on the pre-clinical or early clinical development of genetically engineered immune cells (i.e., CAR-T cells), see 702-704. Health services or outcomes research see 900s.

802. Chemical Biology and Experimental Therapeutics

Application of small molecule design and discovery to understanding and treating blood diseases. This category includes chemical probe discovery, chemical optimization of molecules as therapeutic agents, and comparative analyses of pharmacologic agents in preclinical models. Applications and discovery via proteomics, combinatorial chemistry, target identification and validation, novel screening methodologies, high-throughput assay development, hit-to-lead methodologies, and lead optimization techniques are also appropriate for this category.

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology

The development and testing of new tools, algorithms, and methodologies to improve diagnostics and tailor therapeutics for blood diseases. Includes development of technologies designed for applications in routine clinical care as well as those more appropriate for a research setting. Technologies covered in this category might include new approaches or uses of genome sequencing, epigenomics, RNA-seq, digital PCR, minimum residual disease assays, “multiomics”, microbiome profiling, ex vivo drug sensitivity assays, target specific imaging (or other target-oriented technologies), bioinformatics, artificial intelligence or machine learning, imaging, and immunologic assay development. Application of these tools and assays once established belong in other categories. This category encompasses novel applications of machine learning and deep learning algorithms in both clinical and research hematology.

900s - Health Services, Quality Improvement, and Outcomes Research

900. Health Services and Quality Improvement: Hemoglobinopathies

Health services research on hemoglobinopathies and their treatments. Health services research focuses on the most effective ways to organize, manage, finance, and/or deliver high quality care; reduce medical errors; and improve patient safety. Abstracts focused on quality-improvement studies, economics of hematologic services (cost-effectiveness analyses, cost-benefit/cost-utility analyses, resource utilization, epidemiology of cost), decision analyses, clinical pathways and practice guidelines, patient preference studies, studies of decision aids or other patient tools, informatics (telemedicine, computer decision support), and studies of innovative healthcare delivery models, including in developing countries, belong in this category. Abstracts on how health care services impact patient or population outcomes and registry or Real-World studies belong in 904. Abstracts reporting results from clinical trials do not belong in this category.

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies

Health services research on non-malignant hematologic conditions and their treatments, excluding hemoglobinopathies (see 900), including transplantation or cellular therapies. Health services research focuses on the most effective ways to organize, manage, finance, and/or deliver high quality care; reduce medical errors, and improve patient safety. Abstracts focused on quality-improvement studies, economics of hematologic services (cost-effectiveness analyses, cost-benefit/cost-utility analyses, resource utilization, epidemiology of cost), decision analyses, clinical pathways and practice guidelines, patient preference studies, studies of decision aids or other patient tools, informatics (telemedicine, computer decision support), and studies of innovative healthcare delivery models, including in developing countries, belong in this category. Abstracts on how health care services impact patient or population outcomes and registry or Real-World studies belong in 905. Abstracts reporting results from clinical trials do not belong in this category.

902. Health Services and Quality Improvement: Lymphoid Malignancies

Health services research on lymphoid malignancies should be submitted to this category. Health services research focuses on the most effective ways to organize, manage, finance, and/or deliver high quality care; reduce medical errors, and improve patient safety. Abstracts focused on quality-improvement studies, economics of hematologic services (cost-effectiveness analyses, cost-benefit/cost-utility analyses, resource utilization, epidemiology of cost), decision analyses, clinical pathways and practice guidelines, patient preference studies, studies of decision aids or other patient tools, informatics (telemedicine, computer decision support), and studies of innovative healthcare delivery models, including in developing countries, belong in this category. Abstracts on how health care services impact patient or population outcomes and registry or Real-World studies belong in 906 and 907. Abstracts reporting results from clinical trials do not belong in this category.

903. Health Services and Quality Improvement: Myeloid Malignancies

Health services research on myeloid malignancies should be submitted to this category. Health services research focuses on the most effective ways to organize, manage, finance, and/or deliver high quality care; reduce medical errors; and improve patient safety. Abstracts focused on quality-improvement studies, economics of hematologic services (cost-effectiveness analyses, cost-benefit/cost-utility analyses, resource utilization, epidemiology of cost), decision analyses, clinical pathways and practice guidelines, patient preference studies, studies of decision aids or other patient tools, informatics (telemedicine, computer decision support), and studies of innovative healthcare delivery models, including in developing countries, belong in this category. Abstracts on how health care services impact patient or population outcomes and registry or Real-World studies belong in 908. Abstracts reporting results from clinical trials do not belong in this category.

904. Outcomes Research: Hemoglobinopathies

Outcomes research focuses on how health services impact health outcomes for individuals and populations. Abstracts appropriate for this category focus on patients with hemoglobinopathies and include Real-World data studies, patient-reported outcomes, and registry studies. Outcomes include disease response, quality of life, symptoms, mental health, and other parameters. Studies exploring how factors beyond diagnosis, such as demographic and geography, influence healthcare outcomes also belong in this category. Quality improvement, health systems, and health economic studies belong in 900. Abstracts reporting on prospective therapeutic trials (including clinical trials with a quality-of-life endpoint) are not appropriate for this category.

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies

Outcomes research focuses on how health services impact health outcomes for individuals and populations. Abstracts appropriate for this category focus on patients with hemoglobinopathies and include Real-World data studies, patient-reported outcomes, and registry studies. Outcomes include disease response, quality of life, symptoms, mental health, and other parameters. Studies exploring how factors beyond diagnosis, such as demographic and geography, influence healthcare outcomes also belong in this category. Quality improvement, health systems, and health economic studies belong in 901. Abstracts reporting on prospective therapeutic trials (including clinical trials with a quality-of-life endpoint) are not appropriate for this category.

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders

Outcomes research focuses on how health services impact health outcomes for individuals and populations. Abstracts appropriate for this category focus on patients with lymphoid malignancies (excluding plasma cell disorders) and include Real-World data studies, patient-reported outcomes, and registry studies. Outcomes include disease response, quality of life, symptoms, mental health, and other parameters. Studies based on detailed registries or prospective multicenter observational studies for single disease or disease groups are encouraged to submit to the disease specific category. In particular, Real-World outcomes for CAR-T therapy or bispecific therapy are encouraged to submit to the disease-specific category (e.g. 628 and 629 for aggressive lymphomas, respectively). Other studies focused on a single disease should strongly consider submission to the disease-specific category, e.g. 642 Chronic Lymphocytic Leukemia: Clinical and Epidemiological, if relevant. Studies exploring how factors beyond diagnosis, such as demographic and geography, influence healthcare outcomes belong in this category. Quality improvement, health systems, and health economic studies belong in 902. Abstracts reporting on prospective therapeutic trials (including clinical trials with a quality-of-life endpoint) or prospective registry studies are not appropriate for this category.

907. Outcomes Research: Plasma Cell Disorders

Outcomes research focuses on how health services impact health outcomes for individuals and populations. Abstracts appropriate for this category focus on patients with plasma cell disorders, and include Real-World data studies, patient-reported outcomes, and registry studies. Outcomes include disease response, quality of life, symptoms, mental health, and other parameters. Real-world outcomes for CAR-T therapy or bispecific therapy are encouraged to submit to the disease specific category (e.g. 655 and 654 for multiple myeloma, respectively). Studies exploring how factors beyond diagnosis, such as demographic and geography, influence healthcare outcomes belong in this category. Quality improvement, health systems, and health economic studies belong in 902. Abstracts reporting on prospective therapeutic trials (including clinical trials with a quality-of-life endpoint) are not appropriate for this category.

908. Outcomes Research: Myeloid Malignancies

Outcomes research focuses on how health services impact health outcomes for individuals and populations. Abstracts appropriate for this category focus on patients with myeloid malignancies and include Real-World data studies, patient-reported outcomes, and registry studies. Outcomes include disease response, quality of life, symptoms, mental health, and other parameters. Studies exploring how factors beyond diagnosis, such as demographics and geography, influence healthcare outcomes also belong in this category. Quality improvement, health systems, and health economic studies belong in 903. Abstracts reporting on prospective therapeutic trials (including clinical trials with a quality-of-life endpoint) are not appropriate for this category.

909. Medical Education and Workforce Development

Research on medical and science education, communication, including the use of social media, and the biomedical workforce. Abstracts appropriate for this category focus on all aspects and levels of biomedical trainee and medical practitioner education, career progression and support, trainee and clinician/scientist wellness, and patient and caregiver education. This category also encompasses research on the most effective approaches for communication with and between patients and practitioners. It also includes investigations of the workplace, the workforce, research funding, and other aspects of career progression for trainees, clinicians, and scientists.